Clinical Trials
38 trialsNCT05379595 2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT05846867 2026-03-04
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
Phase 1/2 Active not recruiting
NCT07391566 2026-02-06
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Phase 1/2 Not yet recruiting
NCT00989469 2026-02-05
NEXIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT04689347 2026-01-12
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT01550510 2025-05-06
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
Thomas Jefferson University
Phase 1/2 Terminated
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
NCT05278728 2025-02-07
Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 1/2 Completed
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT00838578 2024-04-26
Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT06202001 2024-04-02
Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2 Recruiting
NCT01133990 2023-11-07
FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT03454620 2022-03-03
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
GC Biopharma Corp
Phase 1/2 Completed
NCT04988191 2021-08-03
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Peking University
Phase 1/2 Unknown
NCT01075048 2021-04-08
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT02244632 2020-09-09
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT00003225 2020-08-03
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT02568046 2019-03-26
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
Symphogen A/S
Phase 1/2 Terminated
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT00003344 2018-05-16
Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
Medical University of South Carolina
Phase 1/2 Completed
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT00361244 2017-02-17
SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Terminated
NCT01675128 2016-04-25
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01008475 2016-03-30
POSEIDON
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00594984 2015-11-04
Phase I/II Combination With Irinotecan- Erbitux
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00522665 2015-05-15
Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer
Hoosier Cancer Research Network
Phase 1/2 Completed
NCT00004870 2013-02-21
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Phase 1/2 Completed
NCT00217711 2012-06-05
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Swiss Cancer Institute
Phase 1/2 Completed
NCT00034502 2006-07-19
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
Eli Lilly and Company
Phase 1/2 Completed
NCT00209625 2005-09-21
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Completed